Investing.com - Glenmark Pharma reported on Friday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Glenmark Pharma announced earnings per share of 7.5 on revenue of 27.77B. Analysts polled by Investing.com anticipated EPS of 7.32 on revenue of 28.72B.
Glenmark Pharma shares are down 23.75% from the beginning of the year, still down 29.47% from its 52 week high of 551.50 set on November 26, 2021. They are under-performing the EUR/USD which is down 0% from the start of the year.
Glenmark Pharma follows other major Healthcare sector earnings this month
Glenmark Pharma's report follows an earnings beat by Divi's Labs on August 12, who reported EPS of 26.4 on revenue of 22.55B, compared to forecasts EPS of 25.88 on revenue of 22.61B.
Max Healthcare Institute had beat expectations on August 31 with second quarter EPS of 2.45 on revenue of 13.93B, compared to forecast for EPS of 2.35 on revenue of 13.92B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar